Grant: CAG/CIHR Fellowship for Research in Gastroenterology/Nutrition
University of Calgary
$60,000.00
The immunomodulatory effects of probiotics in experimental colitis
FY 2008-09
Summary
The etiology of Ulcerative Colitis (UC) include the loss of 'mucosal homoestasis' that under normal conditions differentiate intestinal pathogens from commensals and escalates an immune response against pathogens but remains tolerant to the commensals. The upstream events in UC pathogenesis are change in the density and composition of the intestinal microbiota, a shift in recognition of these luminal antigens and suppression of mucin secretion. The downstream events involve an aberrant inflammatory milieu. The increasing evidence that the critical initial event of UC pathogenesis is change in the composition of the intestinal microbiota led to a more promising therapeutic approach - 'Recomposition of the commensal microbiota with the use of probiotics'. Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. VSL#3 is a probiotic mixture of eight bacterial species, clinically shown to be effective in preventing flare-ups of refractory pouchitis and in remission of UC. The lack of sufficient information on mechanism of probiotics action as an immune-modulator undermines their use. The questions that need to be addressed include (1) whether probiotics is better as a protective or as therapeutic agent? (2) Probiotics perform immune modulation by suppressing the inflammatory response or by inducing the tolerogenic responses or by simply altering the pattern of antigen recognition? and (3) Does a live probiotic bacteria is the pre-requisite of the beneficial effect or a 'probiotic mimic' (a DNA motif or a secreted protein) can induce a similar effect? This proposal evaluates and compares the therapeutic and preventive potential of VSL#3 and examines the mechanism whereby VSL#3 synergizes to promote innate host defenses against experimental colitis. The proposal also examines whether the beneficial effect conferred by the mixture of live probiotic bacteria is comparable/superior than that of a probiotic mimic.
Department
Program
CAG/CIHR Fellowship for Research in Gastroenterology/Nutrition
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
175664
Name
Dharmani Poonam
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Axcan Pharma Inc. (Quebec)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
CIHR - INMD - CAG (Canadian Association of Gastroenterology) Partnership
Projecttitle
The immunomodulatory effects of probiotics in experimental colitis
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CAG/CIHR Fellowship for Research in Gastroenterology/Nutrition
Keyworddelim
Colitis; Dextran Sulphate Sodium; Immuno-Modulatory Effect; Innate Defense; Mucin; Pro-Inflmmatory Cytokines; Probiotics; Regulatory Cytokines; Toll-Like Receptors
Abstract
The etiology of Ulcerative Colitis (UC) include the loss of 'mucosal homoestasis' that under normal conditions differentiate intestinal pathogens from commensals and escalates an immune response against pathogens but remains tolerant to the commensals. The upstream events in UC pathogenesis are change in the density and composition of the intestinal microbiota, a shift in recognition of these luminal antigens and suppression of mucin secretion. The downstream events involve an aberrant inflammatory milieu. The increasing evidence that the critical initial event of UC pathogenesis is change in the composition of the intestinal microbiota led to a more promising therapeutic approach - 'Recomposition of the commensal microbiota with the use of probiotics'. Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. VSL#3 is a probiotic mixture of eight bacterial species, clinically shown to be effective in preventing flare-ups of refractory pouchitis and in remission of UC. The lack of sufficient information on mechanism of probiotics action as an immune-modulator undermines their use. The questions that need to be addressed include (1) whether probiotics is better as a protective or as therapeutic agent? (2) Probiotics perform immune modulation by suppressing the inflammatory response or by inducing the tolerogenic responses or by simply altering the pattern of antigen recognition? and (3) Does a live probiotic bacteria is the pre-requisite of the beneficial effect or a 'probiotic mimic' (a DNA motif or a secreted protein) can induce a similar effect? This proposal evaluates and compares the therapeutic and preventive potential of VSL#3 and examines the mechanism whereby VSL#3 synergizes to promote innate host defenses against experimental colitis. The proposal also examines whether the beneficial effect conferred by the mixture of live probiotic bacteria is comparable/superior than that of a probiotic mimic.
Competitiondate
200810
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dharmani, Poonam
Approvedterm
2 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $60,000~ $0~